Condition: Lipidemia · Type 2 Diabetes (T2DM) · Metabolic Syndrome (MetS) · Sponsor: NewAmsterdam Pharma
This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.
This description comes directly from the study's public registry record.
Gagandeep Dhillon · 519-209-2341 · Gagandeep.dhillon@fortrea.com
Always discuss trial participation with your own doctor first.
| Clinical Research Institute of Arizona | Sun City West, Arizona, United States | Recruiting |
| Scripps Health - Whittier Diabetes Institute | La Jolla, California, United States | Recruiting |
| UF Health Jackson | Jacksonville, Florida, United States | Recruiting |
| East Coast Institute of Research LLC | Jacksonville, Florida, United States | Recruiting |
| East Coast Institute of Research LLC | Lake City, Florida, United States | Recruiting |
| Floridian Clinical Research | Miami Lakes, Florida, United States | Recruiting |
| Louisville Metabolic and Atherosclerosis Research Center (L-MARC) | Louisville, Kentucky, United States | Recruiting |
| MD Medical Research | Oxon Hill, Maryland, United States | Recruiting |
| Jefferson City Medical Group | Jefferson City, Missouri, United States | Recruiting |
| Montana Medical Research | Missoula, Montana, United States | Recruiting |
| Inspira Health - Internal Medicine Associates | Bridgeton, New Jersey, United States | Recruiting |
| Central New York Clinical Research | Manlius, New York, United States | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07219602